- Home
- LBTYK vs RNA Comparison
LBTYK vs RNA Comparison
Compare LBTYK & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYK | RNA |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LBTYK | RNA |
|---|---|---|
| Price | $10.86 | $72.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | 832.1K | ★ 2.2M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,770,600,000.00 | $20,868,000.00 |
| Revenue This Year | $13.82 | $57.30 |
| Revenue Next Year | $1.27 | $28.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.50 | 106.27 |
| 52 Week Low | $9.21 | $21.51 |
| 52 Week High | $13.62 | $72.61 |
Technical Indicators
Market Signals| Indicator | LBTYK | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 73.72 |
| Support Level | $10.40 | $72.04 |
| Resistance Level | $11.25 | $72.20 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | -0.02 | -0.25 |
| Stochastic Oscillator | 51.09 | 68.39 |
Price Performance
Historical ComparisonAbout LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.